Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ikena Oncology stock in Canada | $12.97

Own Ikena Oncology shares in just a few minutes.

Ikena Oncology Inc
NASDAQ: IKNA - USD
BIOTECHNOLOGY
$12.97
- $0.13 ( - 0.99%)

Ikena Oncology is a biotechnology business based in the US. Ikena Oncology stocks (IKNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.33 – a decrease of 1.74% over the previous week. Ikena Oncology employs 50 staff and has a trailing 12-month revenue of around $9.9 million.

How to buy Ikena Oncology stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: IKNA in this case.
  5. Research Ikena Oncology stocks. The platform should provide the latest information available.
  6. Buy your Ikena Oncology stocks. It's that simple.

Is it a good time to buy Ikena Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Ikena Oncology stock price

Use our graph to track the performance of IKNA stocks over time.

Ikena Oncology stocks at a glance

Information last updated 2021-09-12.
Latest market close$12.97
52-week range$9.63 - $37.61
50-day moving average $11.5462
200-day moving average $15.9778
Wall St. target price$27
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.793

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
OFFER
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.

An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
OFFER
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Ikena Oncology price performance over time

Historical closes compared with the last close of $12.97

1 week (2021-09-09) 0.08%
1 month (2021-08-18) 13.87%
3 months (2021-06-18) -2.26%

Ikena Oncology financials

Revenue TTM USD$9.9 million
Gross profit TTM USD$-24,513,000
Return on assets TTM -16.4%
Return on equity TTM -72.35%
Profit margin 0%
Book value $6.031
Market capitalisation USD$555.4 million

TTM: trailing 12 months

How to short and sell Ikena Oncology stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "IKNA.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 1.5 million Ikena Oncology stocks held short by investors – that's known as Ikena Oncology's "short interest". This figure is 2.3% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Ikena Oncology stocks can be evaluated.

Ikena Oncology's "short interest ratio" (SIR)

Ikena Oncology's "short interest ratio" (SIR) is the quantity of Ikena Oncology stocks currently shorted divided by the average quantity of Ikena Oncology stocks traded daily (recently around 166039.03508772). Ikena Oncology's SIR currently stands at 9.12. In other words for every 100,000 Ikena Oncology stocks traded daily on the market, roughly 9120 stocks are currently held short.

To gain some more context, you can compare Ikena Oncology's short interest ratio against those of similar companies.

However Ikena Oncology's short interest can also be evaluated against the total number of Ikena Oncology stocks, or, against the total number of tradable Ikena Oncology stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ikena Oncology's short interest could be expressed as 0.04% of the outstanding stocks (for every 100,000 Ikena Oncology stocks in existence, roughly 40 stocks are currently held short) or 0.1019% of the tradable stocks (for every 100,000 tradable Ikena Oncology stocks, roughly 102 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Ikena Oncology.

Find out more about how you can short Ikena Oncology stock.

Ikena Oncology stock dividends

We're not expecting Ikena Oncology to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Ikena Oncology overview

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site